Medical imaging contrast agent injector

These Optima 8x00 series quartz injectors are used for volatile organic solvent introduction and recommended for a wide range of non-HF applications. Please note: Compatible with ESI press-fit PFA spray chamber connection.

These Optima 8x00 series quartz injectors are used for volatile organic solvent introduction and recommended for a wide range of non-HF applications. Please note: Compatible with ESI press-fit PFA spray chamber connection.

Sapphire injector. HF-resistant. These sapphire injectors are used for environmental, geochemistry, and HF applications on the Optima 8x00 series instruments. Please note: Compatible with ESI press-fit PFA spray chamber connection.

Please note: Compatible with ESI press-fit PFA spray chamber connection.

This injector includes the black PEEK adapter (N0782020) to convert for use with Optima 4000/5000/7000 series instruments. Please note: Compatible with ESI press-fit PFA spray chamber connection.

Ligand-dependent nuclear receptor-interacting factor 1 (LRIF1), also known as RIF1, Receptor-interacting factor 1, and is encoded by the gene LRIF1/C1orf103/RIF1. The retinoic acid receptors (RARs) are ligand-dependent transcription factors that

Phaseal Injector N35-O, 200/cs (Continental US Only) (Drop Ship Requires Pre-Approval)

The system has an unique adaptive read technology - helps reduce false-positive results by examining the sample and compensating for many of the effects of non-specific binding to help deliver a more accurate read. Eliminates the need for visual-read

A neutral RAR&alpha-selective antagonist (Ki = 2.5 nM) antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.

A neutral RAR&alpha-selective antagonist (Ki = 2.5 nM) antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.

A neutral RAR&alpha-selective antagonist (Ki = 2.5 nM) antagonizes agonist-induced coactivator recruitment and moderately decreases SMRT binding to RAR but does not significantly affect nuclear receptor corepressor binding.

InformationENMD-2076 has selective activity againstAurora AandFlt3withIC50of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to RET, SRC, NTRK1/TRKA, CSF1R/FMS, VEGFR2/KDR, FGFR and PDGFRα. ENMD-2076 inhibits the